- Microsoft Office
Patrick Cotogno
Jackson,MS
Summary
Focused clinical researcher with over 10 years of success in designing oncology-oriented programs and developing high performing teams. Accomplished in working with organizational leaders to establish goals and devise strategies driving quality outcomes and organizational growth. Oncology experience includes all phase of clinical research across multiple therapeutic types.
Overview
16
16
years of professional experience
2
2
Certificates
Work History
Director of Operations (oncology)
University Of Mississippi Medical Center
Jackson, MS
10.2020 - Current
- Oversight of all clinical research operations for oncology studies at the Cancer Institute, including start-up activities, budgeting, research billing, regulatory, study conduct, and close-out
- Defined, implemented and revised operational policies and guidelines.
- Led change and transformation across departmental areas to optimize operations and align company resources.
- Modernized and improved operational procedures to increase productivity.
- Monitored study budgets and utilized operational resources.
- Achieved team goals through formalized training plans, coaching and performance management.
- Ensure adherence to federal and local regulations based on FDA and GCP elements
- Experience in all phases of clinical research
- Therapeutic experience includes immunotherapy, radiopharmaceuticals, biologics, chemotherapy, and external beam radiation
Consultant - Subject Matter Expert
CUSP Group (oncology)
Remote
04.2019 - 12.2021
- Leadership role in the development and implementation of a national, multi-site, phase III study
- Trial design and endpoint development through collaborations with major stakeholders
- RFP development and vendor selection
- Clinical and scientific point of contact
- Protocol writing and CRF design
- Support for the development of the medical monitoring plan
- Preparation of scientific slides for presentation
Sr. Clinical Research Coordinator (oncology)
Tulane University Office Of Clinical Research
New Orleans, LA
09.2015 - 10.2020
- Supervised and coordinated more than 50 oncology studies, including phase I – IV in both industry and academia sponsored settings
- Effective study team management through knowledge of oncology, medical practice, and clinical research.
- Collaborated with multiple stakeholders to ensure the highest quality clinical research efforts, including investigators, sponsors, vendors, departments, and patients.
- Participated in continuous improvement by generating suggestions, engaging in problem-solving activities to support teamwork.
- Exceeded goals through effective task prioritization and great work ethic.
Clinical Research Coordinator (oncology)
Tulane University Office Of Clinical Research
New Orleans, LA
02.2012 - 09.2015
- Collected data and followed research protocols, operations manuals and case report form requirements.
- Screened patient records, databases and physician referrals to identify prospective candidates for research studies.
- Worked with principal investigator and sponsors to facilitate daily trial activities and comply with research protocols.
- Collected, evaluated and modeled collected data.
- EDC experience includes RAVE, InForm, TrialMaster, Datalabs, MyTrials, RedCap, and others
Clinical Research Lab Coordinator
Pennington Biomedical Research Center
Baton Rouge, LA
08.2009 - 02.2012
- Hands on experience with clinical research specimen processing, including all major central lab vendors
- Additional experience with Mass Spectrometry
Education
Master of Science - Public Health in Biostatistics
Tulane University School of Public Health and Tropical Medicine
Bachelor of Biological Sciences, College of Basic Science - Business Administration
Louisiana State University, E.J. Ourso College of Business
Skills
- CRF design
Accomplishments
PUBLICATIONS
1. Moses M, Koksal U, Ledet E, Manogue C, Cotogno P, Lewis B, et al. Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. Oncotarget. 2020; 11(1): 15-21.
2. Manogue C, Cotogno P, Ledet E, Lewis B, Wyatt AW, Sartor O. Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer. Oncologist. 2019;2 4(4):444-8.
3. Chapman L, Ledet EM, Barata PC, Cotogno P, Manogue C, Moses M, et al. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men with Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2019.
4. Schiff JP, Cotogno P, Feibus A, Steinwald P, Ledet E, Lewis B, et al. Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. BMC Cancer. 2019;19(1):524.
5. Moses M, Koksal U, Ledet E, Manogue C, Cotogno P, Lewis B, et al. Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. Oncotarget. 2019;11(1).
6. Ranasinghe L, Cotogno P, Ledet E, Bordlee B, Degeyter K, Nguyen N, et al. Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer. Cancer Treat Res Commun. 2019;20:100151.
7. Cotogno PM, Ranasinghe LK, Ledet EM, Lewis BE, Sartor O. Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018;23(7):791-7.
8. McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogno PM, Steinberger AE, et al. Radium-223 Use in Clinical Practice and Variables Associated with Completion of Therapy. Clin Genitourin Cancer. 2017;15(2):e289-e98.
9. Steinberger AE, Cotogno P, Ledet EM, Lewis B, Sartor O. Exceptional Duration of Radium-223 in Prostate Cancer with a BRCA2 Mutation. Clin Genitourin Cancer. 2017;15(1):e69-e71.
10. Steinberger AE, Ledet EM, Luk E, Cotogno P, Stolten M, Desmond D, et al. Characterizations of Clinical and Therapeutic Histories for Men with Prostate Cancer-Specific Mortality. Clin Genitourin Cancer. 2016;14(2):139-48.
PRESENTATIONS
1. Cotogno PM, Moses MM, Ranasinghe L, Christensen BR, Steinwald P, Chapman L, Manogue C, Lewis BE, Layton JL, Sartor AO, Ledet E. ctDNA and copy-number variant quantification in mCRPC at the time of progression. Poster session presented at the meeting of GUASCO 2019, San Francisco, CA
2. Manogue C, Cotogno PM, Moses MM, Barata PC, Layton JL, Sartor AO, Lewis BE. Continuous infusion 5-fluorouracil (5FU) as a novel treatment for heavily pretreated prostate cancer patients: An update. Poster session presented at the meeting of GUASCO 2019, San Francisco, CA
3. Chapman L, Ledet E, Ranasinghe L, Manogue C, Cotogno PM, Moses MM, Christensen BR, Steinwald P, Layton JL, Lewis BE, Sartor AO, Barata PC. TP53 mutations in circulating tumor DNA in men with metastatic castration-resistant prostate cancer mCRPC. Poster session presented at the meeting of GUASCO 2019, San Francisco, CA
4. Vu J, Moses MM, Ranasinghe L, Cotogno PM, Manogue C, Lewis BE, Layton JL, Sartor AO, Ledet E. DNA repair germline pathogenic mutation associations with treatment duration and family history in prostate cancer. Poster session presented at the meeting of GUASCO 2019, San Francisco, CA
5. Chapman L, Ledet EM, Moses MM, Shahbandi A, Steinwald P, Christensen BR, Cotogno PM, Schiff J, Layton JL, Lewis BE, Sartor AO. cfDNA TP53 mutations with treatment history and disease progression in metastatic CRPC. Poster session presented at the meeting of GUASCO 2018, San Francisco, CA
6. Christensen BR, Ledet EM, Moses MM, Chapman L, Steinwald P, Shahbandi A, Cotogno PM, Schiff J, Layton JL, Lewis BE, Sartor AO. Cosegregation of cfDNA AR amplifications and mutations in relation to BRAF and MYC in CRPC. Poster session presented at the meeting of GUASCO 2018, San Francisco, CA
7. Steinwald P, Ledet EM, Christensen BR, Moses MM, Chapman L, Shahbandi A, Schiff J, Cotogno PM, Layton JL, Lewis BE, Schiff J, Sartor AO. Cell-free DNA (cfDNA) analysis and evaluation of BRAF amplifications and mutations in metastatic castration-resistant prostate cancer. Poster session presented at the meeting of GUASCO 2018, San Francisco, CA
'
8. Shahbandi A, Ledet EM, Christensen BR, Moses MM, Steinwald P, Chapman L, Cotogno PM, Layton JL, Lewis BE, Schiff J, Sartor AO. cfDNA analysis of mCRPC patients expressing mutations in Wnt signaling. Poster session presented at the meeting of GUASCO 2018, San Francisco, CA
9. Moses MM, Ledet EM, Ernst EM, Cotogno PM, Schiff J, Lewis BE, Sartor AO. Germline pathologic mutations and cancer family history in prostate cancer patients. Poster session presented at the meeting of GUASCO 2018, San Francisco, CA
10. Cotogno PM, Ranasinghe LK, Ledet EM, Lewis BE, and Sartor AO. Serum-based biomarkers and liver metastases in metastatic castration-resistant prostate cancer (mCRPC). Poster session presented at the meeting of GUASCO 2018, San Francisco, CA
11. Feibus AH, Guccione JR, Vasudevamurthy A, Ledet EM, Cotogno PM, Manogue C, Ernst EM, Lewis BE, Silberstein JL, Sartor AO. Early assessment of PSA response in patients with mCRPC treated with enzalutamide and abiraterone. Poster session presented at the meeting of GUASCO 2017, San Francisco, CA
12. Schiff J, Ledet EM, Ernst EM, Garvey CE, Cotogno PM, Sartor AO. Family history, race, and prostate cancer. Poster session presented at the meeting of GUASCO 2017, San Francisco, CA
13. Chow LD, Cotogno PM, Ernst EM, Manogue C, Ledet EM, Sartor AO. Taste and prostate cancer: Preliminary data on a novel patient-reported outcomes. Poster session presented at the meeting of GUASCO 2017, San Francisco, CA
14. Ledet EM, Schiff J, Cotogno PM, Manogue C, Ernst EM, Lewis, BE, Sartor AO. Association of cfDNA androgen receptor amplifications with BRAF alterations in mCRPC. Poster session presented at the meeting of GUASCO 2017, San Francisco, CA
15. Feibus AH, Vasudevamurthy A, Guccione JR, Ledet EM, Cotogno PM, Manogue C, Ernst EM, Lewis BE, Silberstein JL, Sartor AO. Treatment sequencing of abiraterone and enzalutamide in patients with mCRPC. Poster session presented at the meeting of GUASCO 2017, San Francisco, CA
11. Ranasinghe LK, Cotogno PM, Ledet EM, Steinberger AE, Feibus AH, Degeyter K, Bordlee B. Liver metastases in mCRPC patients post-therapy with abiraterone (Abi) and/or abiraterone/enzalutamide (Enza). Poster session presented at the meeting of GUASCO 2017, San Francisco, CA
16. Cotogno PM, Ledet EM, Schiff J, Manogue C, Lewis BE, Sartor AO. AR amplification eradication with high-dose testosterone (T) in patients with heavily pretreated mCRPC. Poster session presented at the meeting of GUASCO 2017, San Francisco, CA
17. Guccione JR, Ledet EM, Stolten MD, Steinberger AE, Chow LD, Cotogno PM, Lewis BM, Sartor AO. Early assessment of PSA response in CRPC patients treated with enzalutamide (Enza) or abiraterone (Abi). Poster session presented at the meeting of GUASCO 2016, San Francisco, CA
18. Garvey CE, Cotogno PM, Ernst EM, Ledet EM, and Sartor AO. Clinical differences between African-Americans (AA) and Caucasians (CA) with and without family history (FH) of prostate cancer. Poster session presented at the meeting of GUASCO 2016, San Francisco, CA
19. Stolten MD, Steinberger AE, Cotogno PM, Ledet EM, and Sartor AO. Parameters Associated With 6 Cycles of Radium-223 Dichloride Therapy in Metastatic Castrate-Resistant Prostate Cancer. International Journal of Radiation Oncology 2015; 3: E196.
20. Taplin M, Jacobus SJ, Fiorillo M, Ledet EM, Cotogno PM, Steinberger AE, Jacene Ha, Sartor AO, and McKay RR. Clinical practice patterns of Radium-223 (R223) utilization and variables associated with completion of therapy. Poster session presented at the meeting of GUASCO 2015, Orlando, FL.
21. Emamekhoo H, Chowdry RP, Elson P, Ledet EM, Martin A, Cotogno PM, Beach J, Steinberger AE, Allman KD, Stolten MD, Garcia JA, and Sartor AO; Use of radium-223 (Ra-223) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety. Poster session presented at the meeting of GUASCO 2015, Orlando, FL.
22. Steinberger AE, Ledet EM, Luk E, Cotogno PM, Stolten MD, Desmond D, Feibus A, Silberstein JL, and Sartor AO. Characterization of therapies and timelines for men with prostate cancer-specific mortality. Poster session presented at the meeting of GUASCO 2015, Orlando, FL.
23. Cotogno P, Ledet E. M., Steinberger A. E., Chowdry RP, Stolten MD, and Sartor AO. Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer. Poster session presented at the meeting of GUASCO 2015, Orlando, FL.
Software
- Adobe Acrobat
- SAS
- R
- Stata
- EDC
- CTMS
Certification
- CCRP
Timeline
Director of Operations (oncology)
University Of Mississippi Medical Center
10.2020 - Current
Consultant - Subject Matter Expert
CUSP Group (oncology)
04.2019 - 12.2021
Sr. Clinical Research Coordinator (oncology)
Tulane University Office Of Clinical Research
09.2015 - 10.2020
Clinical Research Coordinator (oncology)
Tulane University Office Of Clinical Research
02.2012 - 09.2015
Clinical Research Lab Coordinator
Pennington Biomedical Research Center
08.2009 - 02.2012
Master of Science - Public Health in Biostatistics
Tulane University School of Public Health and Tropical Medicine
Bachelor of Biological Sciences, College of Basic Science - Business Administration
Louisiana State University, E.J. Ourso College of Business
- CCRP
- IATA
Similar Profiles
Courtney CrockettCourtney Crockett
Periop Tech at University of Mississippi Medical Center, UMMCPeriop Tech at University of Mississippi Medical Center, UMMC
Ramona SandlinRamona Sandlin
Director, Informatics and Analytics at University of Mississippi Medical CenterDirector, Informatics and Analytics at University of Mississippi Medical Center
Karen SimonKaren Simon
Registered Nurse at University of Mississippi Medical CenterRegistered Nurse at University of Mississippi Medical Center